Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
Authors:
- Oliver HerrmannOHOliver Herrmann
- Maja Kim KuepperMKMaja Kim Kuepper
- Marlena BütowMBMarlena Bütow
- Ivan G. CostaICIvan G. Costa
- Iris AppelmannIAIris Appelmann
- Fabian BeierFBFabian Beier
- Tom LueddeTLTom Luedde
- Till BraunschweigTBTill Braunschweig
- Steffen KoschmiederSKSteffen Koschmieder
- Tim H. BrümmendorfTBTim H. Brümmendorf
- Mirle SchemionekMSMirle Schemionek
Open Access
- 4 July 2019
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-14
Abstract
Expression of Bcr-Abl in hematopoietic stem cells is sufficient to cause chronic myeloid leukemia (CML) and tyrosine kinase inhibitors (TKI) induce molecular remission in the majority of CML patients. However, the disease driving stem cell population is not fully targeted by TKI therapy, and leukemic stem cells (LSC) capable of re-inducing the disease can persist. Single-cell RNA-sequencing technology recently identified an enriched inflammatory gene signature with TNFα and TGFβ being activated in TKI persisting quiescent LSC. Here, we studied the effects of human TNFα antibody infliximab (IFX), which has been shown to induce anti-inflammatory effects in mice, combined with TKI treatment on LSC function. We first performed GSEA-pathway analysis using our microarray data of murine LSK cells (lin−; Sca-1+; c-kit+) from the SCLtTA/Bcr-Abl CML transgenic mouse model. Bcr-Abl positive cell lines were generated by retroviral transduction. Clonogenic potential was assessed by CFU (colony forming unit). CML mice were treated with nilotinib or nilotinib plus infliximab, and serial transplantation experiments were performed. Likewise to human CML, TNFα signaling was specifically active in murine CML stem cells, and ectopic expression of Bcr-Abl in murine and human progenitor cell lines induced TNFα expression. In vitro exposure to human (IFX) or murine (MP6-XT22) TNFα antibody reduced clonogenic growth of CML cells. Interestingly, TNFα antibody treatment enhanced TKI-induced effects on immature cells in vitro. Additionally, in transplant and serial transplant experiments, using our transgenic CML mouse model, we could subsequently show that IFX therapy boosted TKI-induced effects and further reduced the proportion of malignant stem cells in vivo. TNFα signaling is induced in CML stem cells, and anti-inflammatory therapy enhances TKI-induced decline of LSC, confirming that successful targeting of persisting CML stem cells can be enhanced by addressing their malignant microenvironment simultaneously.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (351546)
- START Inovationsprogramm Forschung, Faculty of Medicine, University Hospital RWTH Aachen (691706)
This publication has 59 references indexed in Scilit:
- TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapyLeukemia, 2016
- Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyBlood, 2013
- Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cellsBlood, 2013
- Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous LeukemiaCancer Cell, 2012
- Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survivalBlood, 2012
- Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatmentBlood, 2011
- IL-6 Controls Leukemic Multipotent Progenitor Cell Fate and Contributes to Chronic Myelogenous Leukemia DevelopmentCancer Cell, 2011
- Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activityJournal of Clinical Investigation, 2011
- Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemiaProceedings of the National Academy of Sciences, 1999
- The Biology of Normal and Neoplastic Stem Cells in CMLLeukemia & Lymphoma, 1993